Fate Therapeutics has announced encouraging initial data from the FT819 phase 1 autoimmunity study for people with ...

All Three Patients Treated in First Dose Cohort Administered Fludarabine-free Conditioning and Show Rapid, Deep, and ...

On Monday, Fate Therapeutics Inc (FATE) stock saw a modest uptick, ending the day at $2.72 which represents a slight increase of $0.07 or 2.64% from the prior close of $2.65. The stock opened at $ and ...

Fate Therapeutics Inc (FATE) stock saw a decline, ending the day at $1.83 which represents a decrease of $-0.09 or -4.69% from the prior close of $1.92. The stock opened at $1.97 and touched a low of ...

Fate Therapeutics, Inc. (NASDAQ:FATE – Get Free Report) has received an average recommendation of “Hold” from the ten ratings ...

Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Hold rating on Fate Therapeutics (FATE – Research Report). The ...

SAN DIEGO, Dec. 03, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to ...

Thrivent Financial for Lutherans increased its holdings in shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) by 24.7% in the third quarter, according to the company in its most recent ...

It has been about a month since the last earnings report for Fate Therapeutics (FATE). Shares have added about 0.5% in that time frame, underperforming the S&P 500. Will the recent positive trend ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

About Fate Therapeutics’ iPSC Product Platform Human induced pluripotent stem cells (iPSCs) possess the unique dual properties of unlimited self-renewal and differentiation potential ...